← Back to search
CLARAMETYX BIOSCIENCES, INC
COLUMBUS, OH, 43212
UnclaimedClaim this profile (free)
Small Business
Subcontracting experience
2 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | URINARY TRACT INFECTIONS (UTIS) ARE AN INCREASING CLINICAL PROBLEM, HAVING INCREASED BY 60% BETWEEN 1990 AND 2019 AND ACCOUNTING FOR 40% OF ALL NOSOCOMIAL INFECTIONS. APPROXIMATELY 65% OF COMPLICATED OR RECURRENT UTIS (RUTIS) ARE DUE TO UROPATHOGENIC E. COLI (UPEC), ALTHOUGH SEVERAL OTHER GRAM-NEGATIVE AND GRAM-POSITIVE PATHOGENS ARE ALSO IMPLICATED. CLARAMETYX BIOSCIENCES, INC. (CLARAMETYX) IS DEVELOPING A VACCINE CANDIDATE, CMTX-301, TO PREVENT RUTIS. CMTX-301 IS A PATHOGEN-AGNOSTIC VACCINE CANDIDATE FOR THE PREVENTION OF BACTERIAL BIOFILMS, A KEY COMPONENT OF MANY RECALCITRANT AND/OR RECURRENT BACTERIAL INFECTIONS, SUCH AS RUTIS. IMMUNIZATION WITH CMTX-301 FOCUSES THE HOST IMMUNE RESPONSE ON SPECIFIC PROTECTIVE EPITOPES WITHIN COMPONENTS OF THE BACTERIAL BIOFILM RESPONSIBLE FOR ITS STRUCTURAL STABILITY, THEREBY PREVENTING BIOFILM FORMATION. GIVEN THAT BIOFILMS ARE A SIGNIFICANT DEFENSE MECHANISM AGAINST DISEASE RESOLUTION, PREVENTING DEVELOPMENT OF THESE PROTECTIVE STRUCTURES SHOULD REDUCE DISEASE OCCURRENCE AND THUS PROVIDE SIGNIFICANT BENEFITS. . UNLIKE OTHER BACTERIAL VACCINES THAT TARGET SPECIFIC BACTERIAL SPECIES, CMTX-301 IMMUNIZATION TO PREVENT BACTERIAL BIOFILM FORMATION WILL ALLOW THE HOST’S NATURAL IMMUNE RESPONSE TO CLEAR INFECTION IN A PATHOGEN-AGNOSTIC MANNER. THE PROGRAM PROPOSED HEREIN WILL ESTABLISH PROOF-OF-CONCEPT PRECLINICAL STUDIES AGAINST RUTI DUE TO E. COLI , DEVELOP A LAB-SCALE MANUFACTURING PROCESS THAT CAN SCALE FOR NEED, AND SEEK FDA GUIDANCE ON THE DEVELOPMENT PROGRAM TO ADVANCE CMTX-301 TO CLINICAL EVALUATION. KC3972 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $384,727 | Dec 17, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | BACTERIAL BIOFILMS HAVE BEEN ESTIMATED TO BE INVOLVED IN 60-80% OF BACTERIAL INFECTIONS. CLARAMETYX BIOSCIENCES, INC. IS DEVELOPING CMTX-101, AN ANTI-DNABII MONOCLONAL ANTIBODY (MAB) THAT RAPIDLY COLLAPSES BACTERIAL BIOFILMS. UNLIKE MOST OTHER ANTI-BIOFILM THERAPEUTICS IN DEVELOPMENT, ANTI-DNABII ANTIBODIES ACT ON BIOFILMS FORMED BY MULTIPLE BACTERIAL PATHOGENS, INCLUDING ALL ESKAPEE PATHOGENS AND ON POLYMICROBIAL BIOFILMS. OUR ANTI-DNABII MAB, CMTX-101, IS RATIONALLY DESIGNED TO TARGET AN IMMUNOPROTECTED REGION OF DNABII PROTEINS AND WILL BE USED IN EMPIRIC THERAPY TOGETHER WITH ANTIBIOTIC STANDARD OF CARE TO TREAT BIOFILM-MEDIATED INFECTIONS. OUR LEAD INDICATION IS TREATING MODERATE TO SEVERE BACTERIAL PNEUMONIA IN HOSPITALIZED PATIENTS. GROUND-BREAKING RESEARCH BY OUR SCIENTIFIC FOUNDERS HAS SHOWN THAT RAPID BIOFILM COLLAPSE ENABLES MORE EFFECTIVE BACTERIAL CLEARANCE BY SEVERAL DIFFERENT MODES OF ACTION. 4500004349 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $840,908 | Sep 14, 2022 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.